About evofem biosciences - EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
EVFM At a Glance
Evofem Biosciences, Inc.
7770 Regents Road
San Diego, California 92122
| Phone | 1-858-550-1900 | Revenue | 20.18M | |
| Industry | Biotechnology | Net Income | 391.00K | |
| Sector | Health Technology | 2025 Sales Growth | 4.235% | |
| Fiscal Year-end | 12 / 2026 | Employees | 29 | |
| View SEC Filings |
EVFM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.023 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 58.051 |
| Enterprise Value to Sales | 5.939 |
| Total Debt to Enterprise Value | 0.455 |
EVFM Efficiency
| Revenue/Employee | 695,965.517 |
| Income Per Employee | 13,482.759 |
| Receivables Turnover | 1.617 |
| Total Asset Turnover | 0.916 |
EVFM Liquidity
| Current Ratio | 0.18 |
| Quick Ratio | 0.167 |
| Cash Ratio | 0.007 |
EVFM Profitability
| Gross Margin | 74.558 |
| Operating Margin | 7.13 |
| Pretax Margin | 1.947 |
| Net Margin | 1.937 |
| Return on Assets | 1.775 |
| Return on Equity | N/A |
| Return on Total Capital | -2.626 |
| Return on Invested Capital | N/A |
EVFM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -366.364 |
| Total Debt to Total Assets | 269.054 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -0.363 |